It is known that PD1/PDL1 are important immune checkpoint components, which mainly regulate the function of tumor cells and TILs (60), and the PD1/PDL1 axis was proved to be a promising therapeutic target in aggressive breast cancers (61). The gene discussed is PDCD1; the disease is breast cancer.